Home2018-11-14T12:11:58+00:00
What we do—

Changing the world

UCLB is the commercialisation company of UCL and its partner NHS Trusts. We bring to market truly world-leading, world-changing technologies, innovations that have a real and positive impact on people’s lives.

Read More
Latest news—

£438 million investment for UCL gene therapy spinouts

UCL spinout Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, has raised $225 million (£173 million) through its initial public offering. The funding success adds to an unprecedented summer that saw UCL spinout companies raise £265 million of investment which could transform patient outcomes.

Read More
Featured Technology—

Novel method of analysis of stroke data

Stroke is the leading cause of adult disability in the UK at an estimated cost of £7 billion a year. UCL has developed a system for predicting clinical outcomes so as to provide advance information on the optimum clinical management of each patient.
Read more
Spotlight—

UCLB Marks 25 Years of Innovation

As this year marks our 25th anniversary, it provides the perfect time to look back on some of the remarkable achievements leading up to this point.

Read More
Featured Technology—

SnakeGrid

SnakeGrid is a way of developing low-distortion coordinate systems for large engineering projects.

Read more

Latest news and highlights

Read More News

UCLTF’s Simon Goldman and David Grimm make the Top 25 of the GUV Powerlist 2018

/ Award Winners, Spinout News
Simon Goldman and David Grimm, who are responsible for managing investments for the UCL Technology Fund, the fund co-managed by ...

£438 million investment for UCL gene therapy spinouts

/ UCLB News
UCL spinout Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene ...

UCLB spinout Orchard Therapeutics announces closing of $225 million Initial Public Offering

/ UCLB News
UCLB spinout Orchard Therapeutics, a biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases ...

Orchard Therapeutics announces pricing of its initial public offering

/ UCLB News
UCLB spinout Orchard Therapeutics has announced the pricing of its initial public offering in the United States of 14,285,715 American ...

FIND THE RIGHT MATCH

Whether you’re an academic or looking for technologies, find your UCLB contact here.

 

Bringing innovation to life

0
Active spinouts
0
Active licences in 2017
0
Drug discoveries
0
New patent applications